bazedoxifene BZA-20

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
76
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postmenopause

Conditions

Postmenopause, Osteoporosis

Trial Timeline

May 1, 2006 โ†’ Sep 1, 2007

About bazedoxifene BZA-20

bazedoxifene BZA-20 is a phase 3 stage product being developed by Pfizer for Postmenopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00384072. Target conditions include Postmenopause, Osteoporosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00384072Phase 3Completed